Will 2013 see more medtech migration into pharma arena?
This article was originally published in Clinica
Executive Summary
Looking ahead at what's in store for 2013, one of the overarching trends that Clinica predicts is the increased presence of medtech players in areas that have until now been traditionally dominated by pharma. This itself could lead to more cross-sector investment/partnerships with pharma firms potentially looking to maintain their stronghold in a disease area and buy medtech alternatives to their drug offering, or medtech firms partnering with pharma to develop the devices required for more effective delivery of drugs.